Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer. Bloomberg reported the figure, citing sources familiar with the deal.
For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac (ranitidine). The company revealed the dismissal of the case and the agreement in a release Thursday.
June 23 (Reuters) - GSK Plc (GSK.L) on Friday said it reached a confidential settlement of a litigation in the United States over claims that the British pharmaceutical giant's heartburn drug Zantac caused cancer.
When Sanofi made an asset swap with Boehringer Ingelheim in 2016, the French company acquired BI’s healthcare business, which included heartburn medicine Zantac.
An Indian court has sentenced two pharmaceutical company executives to two-and-half years in jail for exporting substandard drugs to Vietnam a decade ago, months after the WHO linked their cough syrups to the deaths of children in Gambia.
After years of Zantac heartburn medication legal action, French pharma Sanofi is seeing a resolution to at least some of the litigation.
In yet another turn in the high-profile Zantac litigation, Sanofi and Pfizer agreed to settle a case set for trial in California.
British drugmaker GSK said it has no plans to reintroduce its once top-selling heartburn medication Zinetac (ranitidine) brand in India, despite the US court last week ruling that there is no sound scientific evidence to back the claims that the drug increases the risk of cancer.
New GSK maintains strong start, but Zantac litigation looms large
The central government on Tuesday added at least 34 drugs to the National List of Essential Medicines (NLEM) 2022 and dropped as many as 26 from the previous list. The new list contains a total 384 drugs in comparison to 376 in NLEM 2015. The NLEM 2022 comprises 384 drugs across 27 categories.